JP2019508056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508056A5 JP2019508056A5 JP2018548805A JP2018548805A JP2019508056A5 JP 2019508056 A5 JP2019508056 A5 JP 2019508056A5 JP 2018548805 A JP2018548805 A JP 2018548805A JP 2018548805 A JP2018548805 A JP 2018548805A JP 2019508056 A5 JP2019508056 A5 JP 2019508056A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- baff
- population
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021169476A JP2022023136A (ja) | 2016-03-14 | 2021-10-15 | Ｔ細胞の拡張及び活性化の方法 |
| JP2024063798A JP2024091728A (ja) | 2016-03-14 | 2024-04-11 | Ｔ細胞の拡張及び活性化の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307989P | 2016-03-14 | 2016-03-14 | |
| US62/307,989 | 2016-03-14 | ||
| PCT/US2017/022260 WO2017160806A1 (en) | 2016-03-14 | 2017-03-14 | Methods of t cell expansion and activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169476A Division JP2022023136A (ja) | 2016-03-14 | 2021-10-15 | Ｔ細胞の拡張及び活性化の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508056A JP2019508056A (ja) | 2019-03-28 |
| JP2019508056A5 true JP2019508056A5 (enExample) | 2020-04-23 |
| JP6963560B2 JP6963560B2 (ja) | 2021-11-10 |
Family
ID=58461445
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548805A Active JP6963560B2 (ja) | 2016-03-14 | 2017-03-14 | Ｔ細胞の拡張及び活性化の方法 |
| JP2021169476A Pending JP2022023136A (ja) | 2016-03-14 | 2021-10-15 | Ｔ細胞の拡張及び活性化の方法 |
| JP2024063798A Pending JP2024091728A (ja) | 2016-03-14 | 2024-04-11 | Ｔ細胞の拡張及び活性化の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169476A Pending JP2022023136A (ja) | 2016-03-14 | 2021-10-15 | Ｔ細胞の拡張及び活性化の方法 |
| JP2024063798A Pending JP2024091728A (ja) | 2016-03-14 | 2024-04-11 | Ｔ細胞の拡張及び活性化の方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US10563172B2 (enExample) |
| EP (1) | EP3430130B1 (enExample) |
| JP (3) | JP6963560B2 (enExample) |
| WO (1) | WO2017160806A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3430130B1 (en) * | 2016-03-14 | 2023-01-04 | Wisconsin Alumni Research Foundation | Methods of t cell expansion and activation |
| JP7557367B2 (ja) * | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細針吸引及び小生検からのｔｉｌ拡大培養 |
| WO2025212837A1 (en) * | 2024-04-04 | 2025-10-09 | The Regents Of The University Of Michigan | Enhanced anti-cancer t-cell therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779289B2 (en) | 2000-05-25 | 2005-01-13 | Xcyte Therapies, Inc. | Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression |
| EP1608730B1 (en) * | 2003-03-28 | 2013-11-06 | Biogen Idec MA Inc. | Truncated baff receptors |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| EP3430130B1 (en) * | 2016-03-14 | 2023-01-04 | Wisconsin Alumni Research Foundation | Methods of t cell expansion and activation |
-
2017
- 2017-03-14 EP EP17714950.7A patent/EP3430130B1/en active Active
- 2017-03-14 US US15/458,339 patent/US10563172B2/en active Active
- 2017-03-14 WO PCT/US2017/022260 patent/WO2017160806A1/en not_active Ceased
- 2017-03-14 JP JP2018548805A patent/JP6963560B2/ja active Active
-
2020
- 2020-01-07 US US16/736,389 patent/US12037606B2/en active Active
-
2021
- 2021-10-15 JP JP2021169476A patent/JP2022023136A/ja active Pending
-
2024
- 2024-04-11 JP JP2024063798A patent/JP2024091728A/ja active Pending
- 2024-06-26 US US18/754,949 patent/US20240398695A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Daher et al. | CAR‐NK cells: the next wave of cellular therapy for cancer | |
| Cerwenka et al. | Natural killer cell memory in infection, inflammation and cancer | |
| Lee et al. | Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms | |
| Song et al. | IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation | |
| Patel et al. | Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| Sangiolo | Cytokine induced killer cells as promising immunotherapy for solid tumors | |
| JP2016539929A5 (enExample) | ||
| Lim et al. | GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo | |
| Aftab et al. | Toward “off‐the‐shelf” allogeneic CAR T cells | |
| Ghaedrahmati et al. | Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors | |
| CN104411819B (zh) | 用于过继细胞疗法的改进的细胞培养方法 | |
| JP2020518289A5 (enExample) | ||
| Testa et al. | CAR-T cell therapy in B-cell acute lymphoblastic leukemia | |
| JP2018522072A5 (enExample) | ||
| Smirnov et al. | Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: results of recent clinical trials | |
| Campillo-Davo et al. | Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing | |
| JP2018502114A5 (enExample) | ||
| JP2018512047A5 (enExample) | ||
| Lizana-Vasquez et al. | The application of autologous cancer immunotherapies in the age of memory-NK cells | |
| CN103492406A (zh) | 嵌合抗原受体-修饰的t细胞治疗癌症的用途 | |
| JP2022023136A5 (enExample) | ||
| CN104789595A (zh) | 嵌合抗原受体双阴性t细胞的构建方法 | |
| Beck et al. | Does B cell follicle exclusion of CD8+ T cells make lymph nodes sanctuaries of HIV replication? | |
| JP2018531016A5 (enExample) |